Antimetastatic effect of suicide gene therapy for mouse mammary cancers requires T-cell-mediated immune responses

Medical Molecular Morphology

Volumn 41, Issue 1, 2008, Pages 34-43

  Shibata, Masa Aki ^a   Morimoto, Junji ^a   Akamatsu, Kanako ^a   Otsuki, Yoshinori ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Antimetastasis; HSVtk; IL 12; Immunocompetent; Th1 environment

Indexed keywords

GANCICLOVIR; INTERLEUKIN 12; MESSENGER RNA; PLASMID VECTOR; VASCULOTROPIN A; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; LUNG; LYMPH NODE; LYMPH VESSEL; MACROPHAGE; MOUSE; MOUSE STRAIN; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR CELL; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; ANTIVIRAL AGENTS; BASE SEQUENCE; DNA PRIMERS; FEMALE; GANCICLOVIR; GENE THERAPY; HERPESVIRUS 1, HUMAN; INTERLEUKIN-12; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; RNA, MESSENGER; T-LYMPHOCYTES; THYMIDINE KINASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 43549091587     PISSN: 18601480     EISSN: 18601499     Source Type: Journal    
DOI: 10.1007/s00795-007-0388-1     Document Type: Article

References (31)

1. Moolten I (1994) Drug sensitivity ("suicide") genes for selective cancer therapy. Cancer Gene Ther 1:107-112
2. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550-1552
3. Freeman SM, Ramesh R, Marrogi AJ (1997) Immune system in suicide-gene therapy. Lancet 349:2-3
4. Yamamoto S, Suzuki S, Hoshino A, Akimoto M, Shimada T (1997) Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther 4:91-96
5. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci U S A 93:1831-1835
6. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN (1993) The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274-5283
7. Shibata MA, Morimoto J, Otsuki Y (2002) Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation. Cancer Gene Ther 9:16-27
8. Shibata MA, Morimoto J, Doi H, Morishima S, Naka M, Otsuki Y (2007) Electrogene therapy using endostatin, with or without suicide gene therapy, suppresses murine mammary tumor growth and metastasis. Cancer Gene Ther 14:268-278
9. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palu G (2005) Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12:835-848
10. Shibata MA, Ito Y, Morimoto J, Otsuki Y (2004) Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis (Oxf) 25:1887-1898
11. Morimoto J, Imai S, Haga S, Iwai Y, Iwai M, Hiroishi S, Miyashita N, Moriwaki K, Hosick HL (1991) New murine mammary tumor cell lines. In Vitro Cell Dev Biol 27A:349-351
12. Shibata MA, Akao Y, Shibata E, Nozawa Y, Ito T, Mishima S, Morimoto J, Otsuki Y (2007) Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemother Pharmacol 60:681-691
13. Shibata MA, Morimoto J, Ito Y, Kusakabe K, Otsuki Y (2004) Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer. Med Electron Microsc 37: 216-224
14. Shibata MA, Ito Y, Morimoto J, Kusakabe K, Yoshinaka R, Otsuki Y (2006) In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas. J Gene Med 8:335-352
15. Shibata MA, Liu M-L, Knudson MC, Shibata E, Yoshidome K, Bandy T, Korsmeyer SJ, Green JE (1999) Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-Tag transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 18:2692-2701
16. Gorrin-Rivas MJ, Arii S, Furutani M, Mizumoto M, Mori A, Hanaki K, Maeda M, Furuyama H, Kondo Y, Imamura M (2000) Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res 6:1647-1654
17. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408
18. Shibata MA, Horiguchi T, Morimoto J, Otsuki Y (2003) Massive apoptotic cell death in chemically induced rat urinary bladder carcinomas following in situ HSVtk electrogene transfer. J Gene Med 5:219-231
19. Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Akahane T, Mitoro A, Tominaga K, Tsujinoue H, Yoshiji H, Okamoto S, Fukui H, Ikenaka K (1999) Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer 83:374-380
20. Fogar P, Greco E, Basso D, Habeler W, Navaglia F, Zambon CF, Tormen D, Gallo N, Cecchetto A, Plebani M, Pedrazzoli S (2003) Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur J Surg Oncol 29:721-730
21. Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168
22. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153: 1697-1706
23. Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95-109
24. Rook G, Balkwill F (1998) Cell-mediated immune reactions, 5th edn. Mosby, London
25. Coughlin CM, Wysocka M, Trinchieri G, Lee WM (1997) The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 57:2460-2467
26. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589-596
27. Roy EJ, Gawlick U, Orr BA, Rund LA, Webb AG, Kranz DM (2000) IL-12 treatment of endogenously arising murine brain tumors. J Immunol 165:7293-7299
28. Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H (1998) Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153:103-108
29. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K (1999) VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154:1381-1390
30. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 92: 3566-3570
31. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586